Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs NuvaHealth

Gala Health
Graded #17

Higher grade

vs+8.700000000000003
NuvaHealth
Graded #65

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 74.2/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +8
84
76
Dose & formulationNuvaHealth +5
83
88
Clinical oversightGala Health +3
85
82
Labs & monitoringGala Health +30
83
53
FulfillmentGala Health +14
88
74
Contract termsGala Health +11
66
55
Gala Health · left barNuvaHealth · right bar

The numbers

MetricGala HealthNuvaHealth
WeighScore82.9/10074.2/100
GradeB−C
Scorecard rank#17#65
SemaglutideNot disclosed$139/mo (first-month rate, compounded)
Tirzepatide$179/mo (yearly subscription)$229/mo (first-month rate, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
NuvaHealth

Graded #65 · C

Strengths

  • LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
  • Free and fast delivery + 24/7 patient support disclosed on the home page
  • Newark, DE address suggests a US-incorporated entity (vs offshore)
  • $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
  • $229 first-month price for compounded tirzepatide injection sits in the lower-median range

Where it loses points

  • Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
  • Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
  • Pharmacy partners NOT publicly named — material YMYL transparency gap
  • Per-state availability NOT enumerated; verify your state ships before purchase
  • Lab work + coaching support NOT publicly disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard